Pulse Biosciences Reports Positive Clinical Data for Atrial Fibrillation Treatment

Pulse Biosciences (PLSE) reports promising clinical data from its nPulse Cardiac Catheter feasibility study for atrial fibrillation treatment, demonstrating rapid procedure times and minimal adverse reactions. The study involved 165 patients and showcased the system's safety profile and effectiveness in maintaining pulmonary vein isolation. The company operates in the healthcare sector, focusing on innovative medical devices using Nano-Pulse Stimulation technology.